Clinical Trial

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide as a probe for intestinal UGT activity.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-09-24; most recent amendment 2025-06-29.
Status change: Not Yet Recruiting → Recruiting 2024-03-21
Trial Details
NCT Number NCT06055179
Lead Sponsor Guangzhou University of Traditional Chinese Medicine
Collaborators: University of Houston
Conditions Xiao Chai Hu Tang, Irinotecan-induced Diarrhea
Enrollment 98 participants
Start Date 2024-03-08
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-01